Anakinra
CAR-T Cell Therapy
Ann & Robert H Lurie Children's Hospital of Chicagoprotein_peptidePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the CAR-T Cell Therapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
A-Car028 First Affiliated Hospital of Zhejiang University | Phase 1 | CC |
Chimeric Antigen Receptor Modified T Cells Infusion Second Affiliated Hospital of Guangzhou Medical University | Phase 1 | CC |
Fludarabine TCRCure Biopharma Ltd. | Early Phase 1 | C |
Tc-D101 Car-T TCRCure Biopharma Ltd. | Early Phase 1 | C |
Cyclophosphamide TCRCure Biopharma Ltd. | Early Phase 1 | C |
Ari-0001 The Affiliated Hospital of Xuzhou Medical University | N/A | D |
Axicabtagene Ciloleucel Ruijin Hospital | N/A | D |
Same molecule, other indications
Anakinra is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →